AstraZeneca Pharma India Reports Strong Q2 Results Amid Leadership Change

AstraZeneca Pharma India Limited , a prominent player in the pharmaceutical sector, has announced significant corporate changes alongside its quarterly financial results. The company is navigating through a leadership transition while maintaining robust financial performance.

Leadership Transition

AstraZeneca Pharma India has disclosed that its Company Secretary, Ms. Manasa R, has decided to pursue career opportunities outside the organization. Her last working day is scheduled for November 28, 2025. The company has initiated a search for a suitable replacement to fill this crucial position.

Strong Financial Performance

Alongside this corporate update, AstraZeneca Pharma India has released its financial results for the quarter ended September 30, showcasing substantial growth across key metrics:

Financial Metric	Q2 (Rs in millions)	Q2 Previous Year (Rs in millions)	Year-on-Year Growth
Total Income from Operations	5,652.60	4,161.50	35.80%
Net Profit Before Tax	728.20	510.30	42.70%
Net Profit After Tax	542.20	384.30	41.10%
Earnings Per Share (Rs)	21.69	15.37	41.10%

The company's performance demonstrates significant year-on-year growth, with total income from operations increasing by 35.80% and net profit after tax surging by 41.10% compared to the same quarter in the previous year.

Manufacturing Site Update

AstraZeneca Pharma India has provided an update on its manufacturing operations. The company has ceased operations at its manufacturing site in Bangalore and is currently in the process of selling assets related to the facility. These assets have been reclassified as "Assets held for sale" in compliance with relevant accounting standards.

Looking Ahead

As AstraZeneca Pharma India navigates through these corporate changes and continues its financial performance, the company remains focused on its core operations and future growth strategies. The search for a new Company Secretary and the ongoing process of asset divestment from the manufacturing facility indicate a period of transition for the company.

Investors and stakeholders will be keenly watching how these changes impact the company's operations and financial performance in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.33%	+0.83%	+0.35%	+13.89%	+35.14%	+106.78%

AstraZeneca Pharma India Limited , a leading science-led biopharmaceutical company, has announced impressive financial results for the second quarter of fiscal year 2025-26. The company demonstrated strong performance across its key business segments, reflecting its commitment to innovation and market leadership.

Financial Highlights

AstraZeneca Pharma India reported significant growth in its Q2 FY2025-26 results:

Metric	Q2 FY2025-26	Q2 FY2024-25	YoY Growth
Revenue	₹5,590.90 Cr	₹4,080.00 Cr	37.00%
Net Profit	₹542.20 Cr	₹384.30 Cr	41.00%
EBITDA	₹752.00 Cr	₹524.00 Cr	43.50%
EBITDA Margin	13.45%	12.84%	61 bps

The company's revenue saw a substantial increase of 37% year-over-year, rising from ₹4,080.00 crore in Q2 FY2024-25 to ₹5,590.90 crore in Q2 FY2025-26. This growth was primarily driven by strong performance across the company's therapy areas, particularly in Oncology and Biopharmaceuticals.

Segment-wise Performance

AstraZeneca's growth was broad-based across its key therapeutic areas:

Segment	Q2 FY2025-26 Revenue	YoY Growth
Oncology	₹3,977.50 Cr	48.60%
Biopharmaceuticals (CVRM, R&I, V&I)	₹1,267.50 Cr	7.30%
Rare Disease	₹38.10 Cr	605.60%

The Oncology segment continued to be the primary growth driver, while the Rare Disease segment, though smaller in absolute terms, showed remarkable growth.

Key Developments

During the first half of FY2025-26, AstraZeneca Pharma India achieved several significant milestones:

Received seven new regulatory approvals, reinforcing its leadership across therapy areas.
Launched Eculizumab, the first anti-complement therapy approved in India for treating atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
Gained additional indications for key drugs including Durvalumab, Osimertinib, and Trastuzumab deruxtecan, expanding their use in various cancer treatments.

Management Commentary

Bhavana Agrawal, Chief Financial Officer & Director, stated, "Our strong Q2/H1 results reflect AstraZeneca's strong growth trajectory and unwavering commitment to science-led progress. We continue to strengthen our leadership across therapy areas by advancing an innovation-first portfolio that delivers both patient impact and business value."

Praveen Akkinepally, Country President & Managing Director, added, "Our performance this quarter is a clear testament to AstraZeneca's purpose in action, translating cutting-edge science into life-changing medicines for patients in India. As we scale across our therapy areas, our focus on innovation, partnerships, and patient-centricity is shaping a more accessible and outcomes-driven healthcare ecosystem."

Outlook

With its strong performance in Q2 and the first half of FY2025-26, AstraZeneca Pharma India Limited appears well-positioned to maintain its growth momentum. The company's focus on innovation, expanding its product portfolio, and gaining additional indications for existing drugs is likely to drive future growth and reinforce its market leadership in key therapeutic areas.

Investors and stakeholders can expect AstraZeneca to continue its emphasis on research and development, strategic partnerships, and market expansion to sustain its growth trajectory in the coming quarters.